Quanterix to Participate at the Scotiabank Healthcare 1x1 Day
To learn more about
About
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240617525411/en/
Media Contact:
510-334-6273
quanterix@pancomm.com
Investor Relations Contact:
(508)-789-1725
ir@quanterix.com
Source: